RSNA 2004 

Abstract Archives of the RSNA, 2004


SSG12-07

Long-term Results of Laser Ablation of Liver Metastases of Breast Cancer

Scientific Papers

Presented on November 30, 2004
Presented as part of SSG12: Gastrointestinal (Liver Lesion Ablation: Metatases)

Participants

Martin G. Mack MD, Presenter: Nothing to Disclose
Katrin Eichler MD, Abstract Co-Author: Nothing to Disclose
Ralf Straub MD, Abstract Co-Author: Nothing to Disclose
Thomas Lehnert MD, Abstract Co-Author: Nothing to Disclose
Stefan Zangos MD, Abstract Co-Author: Nothing to Disclose
Thomas Josef Vogl MD, Abstract Co-Author: Nothing to Disclose

PURPOSE

To analyze of the potential of MR-guided laser induced interstitial thermotherapy (LITT) for the treatment of liver metastases of breast cancer.

METHOD AND MATERIALS

279 consecutive patients (average age of 54.8 years, range 23 to 80 years) were treated. 671 metastases were ablated. Survival rates were calculated using the Kaplan-Meier method. 7.7% of the patients had recurrent metastases after surgery, 46.2% metastases in both liver lobes, 25.6% refused surgical resection, 2.2% had contraindications for surgery and 18.3% had metastases at difficult localization for surgery. 41.8% of the metastases were smaller or equal to 2 cm, 33.9 were between 2 and 3 cm, 13.8% were between 3 and 4 cm and 10.4% were larger than 4 cm with a mean of 4.7 cm

RESULTS

All lesions with a maximum diameter of 5 cm could be treated with safety margin of 5-10 mm around the lesion. Also lesions with relationship to the liver capsule, the gall bladder and major vessels were treatable. In patients treated with LITT for liver metastases of breast cancer. The mean survival was 4.5 years (95% CI 3.9 –5.1 years, median 3.4 years) after the first LITT treatment and 5.0 years (95% CI 4.5-5.5 years, median 4.5 years) after the diagnosis of the metastases, which was treated with LITT. The 1 year survival rate was 86%, the 2 year survival rate was 68%, the 3 year survival rate was 54%, and the 5 year survival was 36%. after the first LITT treatment

CONCLUSIONS

A certain number of patients with liver metastases of breast cancer have benefits from local tumor ablation. MR-guided LITT means a safe and effective treatment protocol for liver metastases of breast cancer with improved survival data.

Cite This Abstract

Mack, M, Eichler, K, Straub, R, Lehnert, T, Zangos, S, Vogl, T, Long-term Results of Laser Ablation of Liver Metastases of Breast Cancer.  Radiological Society of North America 2004 Scientific Assembly and Annual Meeting, November 28 - December 3, 2004 ,Chicago IL. http://archive.rsna.org/2004/4411676.html